Sponsor Deadline
Posted: 3/11/2022

Development of HIV Broadly Neutralizing Antibody Susceptibility Assays (R61/R33 Clinical Trial Not Allowed)

This funding opportunity will support high risk, milestone-driven research for the development of innovative assays designed to enable the measurement of HIV susceptibility to broadly neutralizing antibodies (bNAbs) in clinical laboratories. Proposed studies should target early-stage assay development and demonstrate feasibility and clinical utility, followed by verification and late stage validation of the method. Collaborative, interdisciplinary research with partnerships between academia and industry is strongly encouraged.


  • Letter of Intent Due Date(s):30 days prior to the application due date
  • AIDS Application Due Date(s): Aug. 3, 2022

RFA-AI-22-022 Expiration Date Aug. 4, 2022

Amount Description